Regulatory reforms that improve the competitive landscape for biosimilars will promote drug affordability while incentivizing ...
Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...
Pharmacy benefit managers take considerably different approaches to managing patient access to biosimilars, or cheaper ...
Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...
The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...
The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of ...
Omlyclo is used for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, ...
OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for ...
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...
The FDA has approved Celltrion’s OMLYCLO (omalizumab-igec) as the first and only biosimilar designated as interchangeable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback